EUVIMEDEUVIMED entdecken
Crossref

Real-Life Effectiveness of Mepolizumab in Severe Type-2 Chronic Rhinosinusitis with Nasal Polyps: Clinical Outcomes and Predictors of Response

Sante De Santis, Stefania Galassi, Jacopo Cambi

International Archives of Allergy and Immunology · 15.06.2026 · 1-8

DOI: 10.1159/000552667 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, online erschienen am 15.06.2026. Verfasst von Sante De Santis und 2 weiteren Autor:innen. Beteiligte Einrichtung: ENT Department, SS. Annunziata Hospital, Cosenza, Italy. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of the study was to evaluate the real-life effectiveness of mepolizumab in patients with severe uncontrolled type-2 chronic rhinosinusitis with nasal polyps (CRSwNP), focusing on clinical, functional, and inflammatory outcomes.

Methods

This retrospective study included 74 patients with uncontrolled type-2 CRSwNP treated with subcutaneous mepolizumab (100 mg every 4 weeks) for at least 12 months. Primary endpoints were changes in Sino-Nasal Outcome Test-22 (SNOT-22) and Nasal Polyp Score (NPS). Secondary endpoints included Sniffin’ Sticks Identification Test-12 (SSIT-12), Lund-Mackay CT score (LMK-CT), blood eosinophils, total IgE, and Asthma Control Test (ACT). Outcomes were assessed at baseline and at 1, 3, 6, and 12 months.

Results

Significant improvements were observed over 12 months. Mean SNOT-22 decreased from 76.2 ± 17.8 to 27.7 ± 15.6, and NPS from 6.3 ± 0.9 to 2.1 ± 0.7. LMK-CT scores improved from 17.2 ± 3.6 to 10.5 ± 4.2. Olfactory function improved, with normosmia increasing from 2.8% to 10.8%. Blood eosinophils decreased significantly (from 564 ± 62.9 to 82 ± 10.0 cells/μL), while total IgE remained stable. Asthma control improved rapidly, with all patients achieving an ACT of ≥20 within 4 weeks. Multivariate logistic regression identified higher baseline blood eosinophil counts (odds ratio [OR]: 1.42 per 100 cells/μL increase, 95% confidence interval [CI]: 1.08–1.87, p = 0.012) and lower baseline SSIT-12 scores (OR: 0.78 per point increase, 95% CI: 0.63–0.96, p = 0.021) as independent predictors of favorable response at 12 months.

Conclusion

Mepolizumab provides sustained clinical and radiologic improvement in severe type-2 CRSwNP. Baseline eosinophilia and olfactory dysfunction may help identify patients more likely to benefit from anti-IL-5 therapy, supporting a personalized treatment approach.

Schlagwörter

Stichwörter der Autor:innen

Biologic therapyChronic rhinosinusitis with nasal polypsMepolizumabReal-life studyType-2 inflammation

Autor:innen und Institutionen

  • ENT Department, SS. Annunziata Hospital, Cosenza, Italy.
  • Neuroradiology UOC, SS. Annunziata Hospital, Cosenza, Italy.
  • ENT Department, Misericordia Hospital, Azienda USL Toscana Sud Est, Grosseto, Italy, ishajacopo@hotmail.it.

Zitieren

APA

De Santis, S., Galassi, S., & Cambi, J. (2026). Real-Life Effectiveness of Mepolizumab in Severe Type-2 Chronic Rhinosinusitis with Nasal Polyps: Clinical Outcomes and Predictors of Response. International Archives of Allergy and Immunology, 1-8. https://doi.org/10.1159/000552667

Vancouver

De Santis S, Galassi S, Cambi J. Real-Life Effectiveness of Mepolizumab in Severe Type-2 Chronic Rhinosinusitis with Nasal Polyps: Clinical Outcomes and Predictors of Response. International Archives of Allergy and Immunology. 2026:1-8. doi:10.1159/000552667

BibTeX
@article{DeSantis2026,
  author = {De Santis, Sante and Galassi, Stefania and Cambi, Jacopo},
  title = {Real-Life Effectiveness of Mepolizumab in Severe Type-2 Chronic Rhinosinusitis with Nasal Polyps: Clinical Outcomes and Predictors of Response},
  journal = {International Archives of Allergy and Immunology},
  year = {2026},
  pages = {1--8},
  doi = {10.1159/000552667}
}
Kostenlos starten →